Advanced Neurosciences Research, LLC | Fort Collins, CO

Research site

(Unclaimed)

Location

2121 East Harmony Road, 180, Fort Collins, Colorado, United States of America

Site insights

Top conditions

Top treatments

Ocrelizumab

Atogepant

Tyrosine

Bapineuzumab

Tolebrutinib

SAR442168

SAR441344

Galcanezumab

Cladribine

Frexalimab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 36 total trials

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting

Multiple Sclerosis

Drug: Ocrelizumab

Locations recently updated

A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine (ATO EM PEDS)

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Enrolling

Episodic Migraine

Drug: Placebo-Matching Atogepant

Drug: Atogepant

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...

Active, not recruiting

Multiple Sclerosis

Drug: Methylprednisolone

Drug: Antihistamine

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizuma...

Begins enrollment in 1 month

Relapsing-remitting Multiple Sclerosis (RRMS)

Drug: Ocrelizumab (EU)

Drug: Ocrelizumab (US)

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (FREXALT)

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling

Multiple Sclerosis

Drug: Activated charcoal

Drug: Cholestyramine

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling

Multiple Sclerosis

Drug: Frexalimab

Drug: Placebo

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling

Migraine

Drug: Placebo

Drug: Rimegepant

Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine (Kaleidoscope)

A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vo...

Invitation-only

Migraine Prophylaxis

Drug: Atogepant

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Primary Objective:To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple scler...

Active, not recruiting

Primary Progressive Multiple Sclerosis

Drug: Tolebrutinib

Drug: Placebo